<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3634361/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634361/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Journal of hepatology"><meta name="citation_title" content="Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients"><meta name="citation_authors" content="Alexander J. Thompson, Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, Thomas J. Urban, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Nezam H. Afdhal, Ira M. Jacobson, Rafael Esteban, Fred Poordad, Eric J. Lawitz, Jonathan McCone, Mitchell L. Shiffman, Greg W. Galler, John W. King, Paul Y. Kwo, Kevin V. Shianna, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, Mark S. Sulkowski, David B. Goldstein, John G. McHutchison, Andrew J. Muir"><meta name="citation_date" content="February 2012"><meta name="citation_issue" content="2"><meta name="citation_volume" content="56"><meta name="citation_firstpage" content="313"><meta name="citation_doi" content="10.1016/j.jhep.2011.04.021"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3634361/?report=abstract"><meta name="citation_pmid" content="21703177"><meta name="DC.Title" content="Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Alexander J. Thompson"><meta name="DC.Contributor" content="Paul J. Clark"><meta name="DC.Contributor" content="Abanish Singh"><meta name="DC.Contributor" content="Dongliang Ge"><meta name="DC.Contributor" content="Jacques Fellay"><meta name="DC.Contributor" content="Mingfu Zhu"><meta name="DC.Contributor" content="Qianqian Zhu"><meta name="DC.Contributor" content="Thomas J. Urban"><meta name="DC.Contributor" content="Keyur Patel"><meta name="DC.Contributor" content="Hans L. Tillmann"><meta name="DC.Contributor" content="Susanna Naggie"><meta name="DC.Contributor" content="Nezam H. Afdhal"><meta name="DC.Contributor" content="Ira M. Jacobson"><meta name="DC.Contributor" content="Rafael Esteban"><meta name="DC.Contributor" content="Fred Poordad"><meta name="DC.Contributor" content="Eric J. Lawitz"><meta name="DC.Contributor" content="Jonathan McCone"><meta name="DC.Contributor" content="Mitchell L. Shiffman"><meta name="DC.Contributor" content="Greg W. Galler"><meta name="DC.Contributor" content="John W. King"><meta name="DC.Contributor" content="Paul Y. Kwo"><meta name="DC.Contributor" content="Kevin V. Shianna"><meta name="DC.Contributor" content="Stephanie Noviello"><meta name="DC.Contributor" content="Lisa D. Pedicone"><meta name="DC.Contributor" content="Clifford A. Brass"><meta name="DC.Contributor" content="Janice K. Albrecht"><meta name="DC.Contributor" content="Mark S. Sulkowski"><meta name="DC.Contributor" content="David B. Goldstein"><meta name="DC.Contributor" content="John G. McHutchison"><meta name="DC.Contributor" content="Andrew J. Muir"><meta name="DC.Date" content="2012 Feb"><meta name="DC.Identifier" content="10.1016/j.jhep.2011.04.021"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients"><meta property="og:type" content="article"><meta property="og:description" content="Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (peg-IFN)-related thrombocytopenia, ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634361/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC3634361/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC3634361/pdf/nihms380106.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8B8D9CDD5231B10000000007EB0500.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3634361%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="mesh" class="last">MeSH</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC3634361</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">J Hepatol</a></span>. Author manuscript; available in PMC 2013 Apr 24.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=21703177" target="pmc_ext" ref="reftype=publisher&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">J Hepatol. 2012 Feb; 56(2): 313–319. </span></a></div><span class="fm-vol-iss-date">Published online 2011 May 20. </span> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1016%2Fj.jhep.2011.04.021" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.jhep.2011.04.021</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3634361</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS380106</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/21703177">21703177</a></div></div></div></div><h1 class="content-title">Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Thompson%20AJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549844939648" co-class="co-affbox">Alexander J. Thompson</a>,<sup>1,</sup><sup>†</sup> <a href="/pubmed/?term=Clark%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549844697072" co-class="co-affbox">Paul J. Clark</a>,<sup>1,</sup><sup>†</sup> <a href="/pubmed/?term=Singh%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549840225632" co-class="co-affbox">Abanish Singh</a>,<sup>2,</sup><sup>†</sup> <a href="/pubmed/?term=Ge%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549840223024" co-class="co-affbox">Dongliang Ge</a>,<sup>2,</sup><sup>†</sup> <a href="/pubmed/?term=Fellay%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549919103312" co-class="co-affbox">Jacques Fellay</a>,<sup>2</sup> <a href="/pubmed/?term=Zhu%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549838175552" co-class="co-affbox">Mingfu Zhu</a>,<sup>2</sup> <a href="/pubmed/?term=Zhu%20Q%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549838173568" co-class="co-affbox">Qianqian Zhu</a>,<sup>2</sup> <a href="/pubmed/?term=Urban%20TJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549839043696" co-class="co-affbox">Thomas J. Urban</a>,<sup>2</sup> <a href="/pubmed/?term=Patel%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549839041712" co-class="co-affbox">Keyur Patel</a>,<sup>1</sup> <a href="/pubmed/?term=Tillmann%20HL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549841202832" co-class="co-affbox">Hans L. Tillmann</a>,<sup>1</sup> <a href="/pubmed/?term=Naggie%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549841200848" co-class="co-affbox">Susanna Naggie</a>,<sup>1</sup> <a href="/pubmed/?term=Afdhal%20NH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549843412800" co-class="co-affbox">Nezam H. Afdhal</a>,<sup>3</sup> <a href="/pubmed/?term=Jacobson%20IM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549843410816" co-class="co-affbox">Ira M. Jacobson</a>,<sup>4</sup> <a href="/pubmed/?term=Esteban%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549841985232" co-class="co-affbox">Rafael Esteban</a>,<sup>5</sup> <a href="/pubmed/?term=Poordad%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549841983248" co-class="co-affbox">Fred Poordad</a>,<sup>6</sup> <a href="/pubmed/?term=Lawitz%20EJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549837438480" co-class="co-affbox">Eric J. Lawitz</a>,<sup>7</sup> <a href="/pubmed/?term=McCone%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549837436496" co-class="co-affbox">Jonathan McCone</a>,<sup>8</sup> <a href="/pubmed/?term=Shiffman%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549840476640" co-class="co-affbox">Mitchell L. Shiffman</a>,<sup>9</sup> <a href="/pubmed/?term=Galler%20GW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549840474656" co-class="co-affbox">Greg W. Galler</a>,<sup>10</sup> <a href="/pubmed/?term=King%20JW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549881434976" co-class="co-affbox">John W. King</a>,<sup>11</sup> <a href="/pubmed/?term=Kwo%20PY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549881432992" co-class="co-affbox">Paul Y. Kwo</a>,<sup>12</sup> <a href="/pubmed/?term=Shianna%20KV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549844827840" co-class="co-affbox">Kevin V. Shianna</a>,<sup>2</sup> <a href="/pubmed/?term=Noviello%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549844825856" co-class="co-affbox">Stephanie Noviello</a>,<sup>13</sup> <a href="/pubmed/?term=Pedicone%20LD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549836291920" co-class="co-affbox">Lisa D. Pedicone</a>,<sup>13</sup> <a href="/pubmed/?term=Brass%20CA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549836289936" co-class="co-affbox">Clifford A. Brass</a>,<sup>13</sup> <a href="/pubmed/?term=Albrecht%20JK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549845791760" co-class="co-affbox">Janice K. Albrecht</a>,<sup>13</sup> <a href="/pubmed/?term=Sulkowski%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549845789776" co-class="co-affbox">Mark S. Sulkowski</a>,<sup>14</sup> <a href="/pubmed/?term=Goldstein%20DB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549836031936" co-class="co-affbox">David B. Goldstein</a>,<sup>2</sup> <a href="/pubmed/?term=McHutchison%20JG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549836029952" co-class="co-affbox">John G. McHutchison</a>,<sup>1</sup> and  <a href="/pubmed/?term=Muir%20AJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177" class="affpopup" co-rid="_co_idm140549839047904" co-class="co-affbox">Andrew J. Muir</a><sup>1,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140549844939648"><h3 class="no_margin">Alexander J. Thompson</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Thompson%20AJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Alexander J. Thompson</a></div></div><div id="_co_idm140549844697072"><h3 class="no_margin">Paul J. Clark</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Clark%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Paul J. Clark</a></div></div><div id="_co_idm140549840225632"><h3 class="no_margin">Abanish Singh</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Singh%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Abanish Singh</a></div></div><div id="_co_idm140549840223024"><h3 class="no_margin">Dongliang Ge</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Ge%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Dongliang Ge</a></div></div><div id="_co_idm140549919103312"><h3 class="no_margin">Jacques Fellay</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Fellay%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Jacques Fellay</a></div></div><div id="_co_idm140549838175552"><h3 class="no_margin">Mingfu Zhu</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Zhu%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Mingfu Zhu</a></div></div><div id="_co_idm140549838173568"><h3 class="no_margin">Qianqian Zhu</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Zhu%20Q%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Qianqian Zhu</a></div></div><div id="_co_idm140549839043696"><h3 class="no_margin">Thomas J. Urban</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Urban%20TJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Thomas J. Urban</a></div></div><div id="_co_idm140549839041712"><h3 class="no_margin">Keyur Patel</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Patel%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Keyur Patel</a></div></div><div id="_co_idm140549841202832"><h3 class="no_margin">Hans L. Tillmann</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Tillmann%20HL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Hans L. Tillmann</a></div></div><div id="_co_idm140549841200848"><h3 class="no_margin">Susanna Naggie</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Naggie%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Susanna Naggie</a></div></div><div id="_co_idm140549843412800"><h3 class="no_margin">Nezam H. Afdhal</h3><p><sup>3</sup>Beth Israel Deaconess Medical Centre, Boston, MA, USA</p><div>Find articles by <a href="/pubmed/?term=Afdhal%20NH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Nezam H. Afdhal</a></div></div><div id="_co_idm140549843410816"><h3 class="no_margin">Ira M. Jacobson</h3><p><sup>4</sup>Weill Cornell Medical College, New York, NY, USA</p><div>Find articles by <a href="/pubmed/?term=Jacobson%20IM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Ira M. Jacobson</a></div></div><div id="_co_idm140549841985232"><h3 class="no_margin">Rafael Esteban</h3><p><sup>5</sup>Hospital General Universitario Valle de Hebron, CIBERehd del Instituto Carlos III, Barcelona, Spain</p><div>Find articles by <a href="/pubmed/?term=Esteban%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Rafael Esteban</a></div></div><div id="_co_idm140549841983248"><h3 class="no_margin">Fred Poordad</h3><p><sup>6</sup>Cedars-Sinai Medical Center, Los Angeles, CA, USA</p><div>Find articles by <a href="/pubmed/?term=Poordad%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Fred Poordad</a></div></div><div id="_co_idm140549837438480"><h3 class="no_margin">Eric J. Lawitz</h3><p><sup>7</sup>Alamo Medical Research, San Antonio, TX, USA</p><div>Find articles by <a href="/pubmed/?term=Lawitz%20EJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Eric J. Lawitz</a></div></div><div id="_co_idm140549837436496"><h3 class="no_margin">Jonathan McCone</h3><p><sup>8</sup>Mt. Vernon Endoscopy Center, Alexandria, VA, USA</p><div>Find articles by <a href="/pubmed/?term=McCone%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Jonathan McCone</a></div></div><div id="_co_idm140549840476640"><h3 class="no_margin">Mitchell L. Shiffman</h3><p><sup>9</sup>Liver Institute of Virginia, Newport News, VA, USA</p><div>Find articles by <a href="/pubmed/?term=Shiffman%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Mitchell L. Shiffman</a></div></div><div id="_co_idm140549840474656"><h3 class="no_margin">Greg W. Galler</h3><p><sup>10</sup>Kelsey Research Foundation, Houston, TX, USA</p><div>Find articles by <a href="/pubmed/?term=Galler%20GW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Greg W. Galler</a></div></div><div id="_co_idm140549881434976"><h3 class="no_margin">John W. King</h3><p><sup>11</sup>Louisiana State University, Shreveport, LA, USA</p><div>Find articles by <a href="/pubmed/?term=King%20JW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">John W. King</a></div></div><div id="_co_idm140549881432992"><h3 class="no_margin">Paul Y. Kwo</h3><p><sup>12</sup>Indiana University School of Medicine, Indianapolis, IN, USA</p><div>Find articles by <a href="/pubmed/?term=Kwo%20PY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Paul Y. Kwo</a></div></div><div id="_co_idm140549844827840"><h3 class="no_margin">Kevin V. Shianna</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Shianna%20KV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Kevin V. Shianna</a></div></div><div id="_co_idm140549844825856"><h3 class="no_margin">Stephanie Noviello</h3><p><sup>13</sup>Schering-Plough Research Institute (now Merck, Inc.), USA</p><div>Find articles by <a href="/pubmed/?term=Noviello%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Stephanie Noviello</a></div></div><div id="_co_idm140549836291920"><h3 class="no_margin">Lisa D. Pedicone</h3><p><sup>13</sup>Schering-Plough Research Institute (now Merck, Inc.), USA</p><div>Find articles by <a href="/pubmed/?term=Pedicone%20LD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Lisa D. Pedicone</a></div></div><div id="_co_idm140549836289936"><h3 class="no_margin">Clifford A. Brass</h3><p><sup>13</sup>Schering-Plough Research Institute (now Merck, Inc.), USA</p><div>Find articles by <a href="/pubmed/?term=Brass%20CA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Clifford A. Brass</a></div></div><div id="_co_idm140549845791760"><h3 class="no_margin">Janice K. Albrecht</h3><p><sup>13</sup>Schering-Plough Research Institute (now Merck, Inc.), USA</p><div>Find articles by <a href="/pubmed/?term=Albrecht%20JK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Janice K. Albrecht</a></div></div><div id="_co_idm140549845789776"><h3 class="no_margin">Mark S. Sulkowski</h3><p><sup>14</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA</p><div>Find articles by <a href="/pubmed/?term=Sulkowski%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Mark S. Sulkowski</a></div></div><div id="_co_idm140549836031936"><h3 class="no_margin">David B. Goldstein</h3><p><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Goldstein%20DB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">David B. Goldstein</a></div></div><div id="_co_idm140549836029952"><h3 class="no_margin">John G. McHutchison</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=McHutchison%20JG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">John G. McHutchison</a></div></div><div id="_co_idm140549839047904"><h3 class="no_margin">Andrew J. Muir</h3><p><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</p><div>Find articles by <a href="/pubmed/?term=Muir%20AJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21703177">Andrew J. Muir</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140549846140912_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140549846140912_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140549846140912_ai" style="display:none"><div class="fm-affl" id="A1" lang="en"><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA</div><div class="fm-affl" id="A2" lang="en"><sup>2</sup>Center for Human Genome Variation, Duke University, Durham, NC, USA</div><div class="fm-affl" id="A3" lang="en"><sup>3</sup>Beth Israel Deaconess Medical Centre, Boston, MA, USA</div><div class="fm-affl" id="A4" lang="en"><sup>4</sup>Weill Cornell Medical College, New York, NY, USA</div><div class="fm-affl" id="A5" lang="en"><sup>5</sup>Hospital General Universitario Valle de Hebron, CIBERehd del Instituto Carlos III, Barcelona, Spain</div><div class="fm-affl" id="A6" lang="en"><sup>6</sup>Cedars-Sinai Medical Center, Los Angeles, CA, USA</div><div class="fm-affl" id="A7" lang="en"><sup>7</sup>Alamo Medical Research, San Antonio, TX, USA</div><div class="fm-affl" id="A8" lang="en"><sup>8</sup>Mt. Vernon Endoscopy Center, Alexandria, VA, USA</div><div class="fm-affl" id="A9" lang="en"><sup>9</sup>Liver Institute of Virginia, Newport News, VA, USA</div><div class="fm-affl" id="A10" lang="en"><sup>10</sup>Kelsey Research Foundation, Houston, TX, USA</div><div class="fm-affl" id="A11" lang="en"><sup>11</sup>Louisiana State University, Shreveport, LA, USA</div><div class="fm-affl" id="A12" lang="en"><sup>12</sup>Indiana University School of Medicine, Indianapolis, IN, USA</div><div class="fm-affl" id="A13" lang="en"><sup>13</sup>Schering-Plough Research Institute (now Merck, Inc.), USA</div><div class="fm-affl" id="A14" lang="en"><sup>14</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA</div><div id="FN1"><sup>*</sup>Corresponding author. Address: Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Terrace Level, Room 0311, Durham, NC 27701, USA. Tel.: +1 919 668 8557; fax: +1 919 668 7164. <a href="mailto:dev@null" data-email="ude.ekud.cm@2000rium" class="oemail">ude.ekud.cm@2000rium</a> (A.J. Muir)</div><div id="FN2"><sup>†</sup>These authors contributed equally to the work.</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140549846140912_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=21703177" target="pmc_ext" ref="reftype=publisher&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">J Hepatol</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC3634361/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Suppl data.</strong></div><div><a href="/pmc/articles/PMC3634361/bin/NIHMS380106-supplement-Suppl_data.doc" data-ga-action="click_feat_suppl">NIHMS380106-supplement-Suppl_data.doc</a><span style="color:gray"> (3.9M)</span></div><div class="small guid">GUID:&nbsp;01195831-C4BD-41C8-A1CF-CA58300BF79B</div></div></dd></dl></div><div id="idm140549843309248" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140549843309248title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Background &amp; Aims</h3><p id="P1" class="p p-first-last">Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (peg-IFN)-related thrombocytopenia, neutropenia, and leukopenia.</p></div><div id="S2" class="sec"><h3 id="S2title">Methods</h3><p id="P2" class="p p-first-last">1604/3070 patients in the IDEAL study consented to genetic testing. Trial inclusion criteria included a platelet (Pl) count ≥80 × 10<sup>9</sup>/L and an absolute neutrophil count (ANC) ≥ 1500/mm<sup>3</sup>. Samples were genotyped using the Illumina Human610-quad BeadChip. The primary analyses focused on the genetic determinants of quantitative change in cell counts (Pl, ANC, lymphocytes, monocytes, eosinophils, and basophils) at week 4 in patients &gt;80% adherent to therapy (n = 1294).</p></div><div id="S3" class="sec"><h3 id="S3title">Results</h3><p id="P3" class="p p-first-last">6 SNPs on chromosome 20 were positively associated with Pl reduction (top SNP rs965469, <em>p</em> = 10<sup>−10</sup>). These tag SNPs are in high linkage disequilibrium with 2 functional variants in the <em>ITPA</em> gene, rs1127354 and rs7270101, that cause ITPase deficiency and protect against ribavirin (RBV)-induced hemolytic anemia (HA). rs1127354 and rs7270101 showed strong independent associations with Pl reduction (<em>p</em> = 10<sup>−12</sup>, <em>p</em> = 10<sup>−7</sup>) and entirely explained the genome-wide significant associations. We believe this is an example of an indirect genetic association due to a reactive thrombocytosis to RBV-induced anemia: Hb decline was inversely correlated with Pl reduction (r = −0.28, <em>p</em> = 10<sup>−17</sup>) and Hb change largely attenuated the association between the <em>ITPA</em> variants and Pl reduction in regression models. No common genetic variants were associated with pegIFN-induced neutropenia or leucopenia.</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">Conclusions</h3><p id="P4" class="p p-first-last">Two <em>ITPA</em> variants were associated with thrombocytopenia; this was largely explained by a thrombocytotic response to RBV-induced HA attenuating IFN-related thrombocytopenia. No genetic determinants of pegIFN-induced neutropenia were identified.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">GWAS, ITPA, Thrombocytopenia, Hepatitis C, Neutropenia, IL28B</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Introduction</h2><p id="P5" class="p p-first">Chronic infection with hepatitis C virus (HCV) affects up to 170 million individuals worldwide [<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766576">1</a>] and may lead to progressive hepatic fibrosis and cirrhosis with risk of liver failure and hepato-cellular carcinoma. HCV-related liver disease is currently the most common indication for liver transplantation in North America. Antiviral therapy with pegylated-interferon-alfa (pegIFN) plus ribavirin (RBV) may be curative, but is poorly tolerated by many patients.</p><p id="P6">Bone marrow suppression is an important adverse effect of pegIFN therapy, leading to neutropenia and thrombocytopenia, with risk of secondary sepsis and bleeding, respectively [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766609">2</a>,<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766597">3</a>]. Dose reduction may be required potentially compromising treatment outcome, as rates of viral clearance are significantly reduced in patients who cannot be maintained on at least 80% of their pegIFN and ribavirin dosage for the duration of treatment [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766594">4</a>]. Identifying patients at greatest risk for such complications would be clinically useful for selecting patients for therapy, as well as planning the frequency of monitoring and likely need for growth factor support on treatment. Patients with advanced hepatic fibrosis are at highest risk [<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766593">5</a>], but bone marrow suppression remains prevalent in patients with early stage fibrosis and there is a need for more accurate biomarkers. A genetic biomarker for predicting risk of IFN-related bone marrow suppression would be particularly useful as a pre-treatment test.</p><p id="P7">A number of lines of evidence suggest that genetic variants may be associated with IFN-induced cytopenia. Firstly, persistently low neutrophil counts are more commonly observed in persons of African American ancestry compared to Caucasians (‘benign ethnic neutropenia’) [<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766607">6</a>], and this has recently been linked to a regulatory variant in the Duffy Antigen Receptor for Chemokines gene (<em>DARC</em>) [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766592">7</a>]. The relevance of this variant to drug-induced neutropenia is not known. Secondly, polymorphism in the region of the interleukin 28B gene (<em>IL28B</em>), coding for IFN-lambda(λ)-3, has recently been identified to be strongly associated with viral clearance following pegIFN plus RBV therapy [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766601">8</a>–<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766591">11</a>]. Although the mechanism remains unclear, the polymorphism is believed to regulate sensitivity to the antiviral effects of IFN. Whether <em>IL28B</em> polymorphism is relevant to other IFN-mediated effects has not been evaluated. Finally, functional variants in the inosine triphosphatase gene (<em>ITPA</em>) causing inosine triphosphatase (ITPase) deficiency, previously recognized as a benign red cell enzymopathy, have recently been identified to protect against RBV-induced hemolytic anemia [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766573">12</a>,<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766610">13</a>]. RBV depletes red cell GTP levels, leading in turn to ATP depletion, oxidative stress, and hemolysis. The protective <em>ITPA</em> variants are associated with red cell inosine triphosphate (ITP) accumulation, and it has been shown that ITP is able to substitute for GTP in the biosynthesis of ATP, thereby protecting against RBV-hemolysis [<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766608">14</a>].</p><p id="P8" class="p p-last">In this study we have performed genome-wide analyses for determinants of treatment-related bone marrow suppression in a large, well characterized cohort of genotype 1 HCV patients treated with pegIFN plus RBV in the IDEAL study. We have focused primarily on treatment-induced neutropenia and thrombocytopenia.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Materials and methods</h2><div id="S7" class="sec sec-first"><h3 id="S7title">Patient and control population</h3><p id="P9" class="p p-first-last">1604/3070 patients in the IDEAL study [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766582">15</a>] consented to collection of DNA samples for genetic testing (ClinicalTrials.gov number, <a id="__tag_563075807" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00081770" ref="reftype=extlink-clinical-trial&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00081770","term_id":"NCT00081770"}}</span>NCT00081770</a>). Clinical and laboratory data were collected as described previously [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766600">15</a>,<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766611">16</a>]. All patients included in this study were treatment-naïve and infected with genotype 1 HCV [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766572">15</a>]. Patients were treated with either pegIFN-alfa-2b (1.0 or 1.5 μg/kg/week) or pegIFN-alfa-2a (180 μg/week) plus weight-based RBV (800–1400 mg for peg-IFN-alfa-2b, and 1000–1200 mg for pegIFN-alfa-2a) [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766580">15</a>]. For all patients, the protocol-specified treatment duration was 48 weeks, with an additional 24 weeks follow-up. All patients had a full blood count performed at baseline, weeks 2, 4, 8, 12, 18, 24, 30, 36, 42, and 48 of therapy and at weeks 4, 12, and 24 post-treatment. Inclusion criteria for the parent study required an absolute neutrophil count (ANC) ≥ 1500/mm<sup>3</sup> and platelet count (Pl) ≥80 × 10<sup>9</sup>/L. All patients had compensated liver disease. Protocol specified dose reduction of pegIFN was indicated for ANC &lt;750/mm<sup>3</sup> or Pl &lt;50 × 10<sup>9</sup>/L, and discontinuation of both pegIFN and RBV was required for ANC &lt;500/mm<sup>3</sup> or Pl &lt;25 × 10<sup>9</sup>/L. The use of growth factor support for neutropenia or thrombocytopenia was not permitted. Detailed records of drug compliance were kept for all patients on-treatment. Only patients who were more than 80% adherent to pegIFN to week 4 of treatment were included in the primary analyses (26 patients were excluded from analysis).</p></div><div id="S8" class="sec"><h3 id="S8title">Genotyping</h3><p id="P10" class="p p-first-last">A total of 1604 DNA samples were genotyped in the context of a previously reported study of anti-HCV treatment response, using the Illumina Human610-quad BeadChip (Illumina, San Diego, CA, USA) as previously described [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766604">8</a>]. Quality control steps are described in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Material I</a>. Genotyping of the two <em>ITPA</em> variants, rs1127354 and rs7270101, was performed using the ABI TaqMan allelic discrimination kit (Applied Biosystems, Carlsbad, CA, USA) in a previous study of RBV-induced hemolytic anemia [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766602">12</a>,<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766586">17</a>].</p></div><div id="S9" class="sec"><h3 id="S9title">Definition of clinical endpoints</h3><p id="P11" class="p p-first-last">The primary analyses focused on the genetic determinants of quantitative change in (i) platelet, and (ii) leukocyte counts, at week 4 of treatment in adherent patients. The following leukocyte sub-populations were separately analyzed: absolute neutrophil count (ANC), lymphocytes, monocytes, basophils, and eosinophils. Week 4 was chosen as a time point to minimize confounding by dose modification of pegIFN and RBV, or confounding by the use of erythropoietin supplementation.</p></div><div id="S10" class="sec sec-last"><h3 id="S10title">Statistical analysis</h3><p id="P12" class="p p-first-last">The primary association tests involved single-marker genotype trend tests performed in three independent groups (European-Americans, African-Americans, Hispanics), using a linear regression model. Association tests were implemented in the PLINK software [<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766614">18</a>], correcting for the relevant clinical covariates baseline cell count (Pl, leukocyte cell lines), age, gender, body mass index, liver fibrosis stage (METAVIR F0–2 <em>vs</em>. F3–4), pegIFN dose (binary variable: pegIFN-α2b 1.0 μg/kg/week <em>vs</em>. pegIFN- α2b 1.5 μg/kg/week and RBV dose (mg/kg). The association signals (<em>p</em> values) were then combined using Stouffer's weighted Z-method [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766589">19</a>], adjusting for sample sizes, effect sizes and effect directions in each population. This combined <em>p</em> value was then reported as the main result, along with the <em>p</em> values in each ethnic group. A series of quality control steps resulted in 565,759 polymorphisms being included in the association tests. Methods to assess copy number variants were applied and the relation between copy number variants and reduction of Pl/leukocyte cell lines was tested. To control for the possibility of spurious associations resulting from population stratification, we used a modified EIGENSTRAT method [<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766598">20</a>] and corrected for population ancestry within each group. We assessed significance with a Bonferroni correction (P<sub>cutoff</sub>= 4.4 × 10<sup>−8</sup>).</p></div></div><div id="S11" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S11title">Results</h2><div id="S12" class="sec sec-first"><h3 id="S12title">Interferon-alfa-mediated thrombocytopenia</h3><p id="P13" class="p p-first">We performed a genome-wide association study (GWAS) of genetic determinants of IFN-related thrombocytopenia at week 4 in compliant genotype 1 HCV patients from the IDEAL study. Following quality control steps, 1284 individuals (984 European-Americans, 201 African-Americans, 99 Hispanics) were included in the analysis (patient characteristics are summarized in <a href="/pmc/articles/PMC3634361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). Baseline Pl counts were not significantly different between the 3 populations (<em>p</em> = 0.8977, <a href="/pmc/articles/PMC3634361/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). We tested each of 565,759 single nucleotide polymorphisms (SNPs) passing quality control measures in a linear regression model incorporating the relevant clinical covariates: age, gender, body mass index (BMI), hepatic fibrosis stage, pegIFN dose (binary: pegIFN-alfa-2b 1.0 μg/kg/week vs. pegIFN-alfa-2b 1.5 μg/kg/week or pegIFN-alfa-2a 180 μg/week), RBV dose (mg/kg) and baseline Pl count.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Patient characteristics</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549831807936" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left"></th><th rowspan="1" colspan="1" valign="top" align="left">European Americans</th><th rowspan="1" colspan="1" valign="top" align="left">African Americans</th><th rowspan="1" colspan="1" valign="top" align="left">Hispanics</th><th rowspan="1" colspan="1" valign="top" align="left"><em>p</em> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">No (platelet analysis)</td><td rowspan="1" colspan="1" valign="top" align="left">984</td><td rowspan="1" colspan="1" valign="top" align="left">201</td><td rowspan="1" colspan="1" valign="top" align="left">99</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Gender (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left">608 (62%)</td><td rowspan="1" colspan="1" valign="top" align="left">121 (60%)</td><td rowspan="1" colspan="1" valign="top" align="left">63 (64%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.8387</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Age, yrs<sup>*</sup></td><td rowspan="1" colspan="1" valign="top" align="left">48 (44-52)</td><td rowspan="1" colspan="1" valign="top" align="left">50 (47-54)</td><td rowspan="1" colspan="1" valign="top" align="left">46 (39-51)</td><td rowspan="1" colspan="1" valign="top" align="left">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">BMI, kg/m<sup>2</sup></td><td rowspan="1" colspan="1" valign="top" align="left">27.4 (24.8-30.4)</td><td rowspan="1" colspan="1" valign="top" align="left">29.3 (26.6-32.6)</td><td rowspan="1" colspan="1" valign="top" align="left">28.6 (25.1-32.8)</td><td rowspan="1" colspan="1" valign="top" align="left">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">METAVIR fibrosis stage (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left">873 (89%)</td><td rowspan="1" colspan="1" valign="top" align="left">183 (91%)</td><td rowspan="1" colspan="1" valign="top" align="left">85 (86%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.3886</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Minimal (F0-2)</td><td rowspan="1" colspan="1" valign="top" align="left">111 (11%)</td><td rowspan="1" colspan="1" valign="top" align="left">18 (9%)</td><td rowspan="1" colspan="1" valign="top" align="left">14 (14%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Advanced (F3-4)</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">RBV starting dose, mg/kg</td><td rowspan="1" colspan="1" valign="top" align="left">13.2 (12.4-14.1)</td><td rowspan="1" colspan="1" valign="top" align="left">12.8 (12.1-13.7)</td><td rowspan="1" colspan="1" valign="top" align="left">13.6 (12.5-14.7)</td><td rowspan="1" colspan="1" valign="top" align="left">0.0004</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">RBV starting dose (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">0.0065</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 800 mg</td><td rowspan="1" colspan="1" valign="top" align="left">86 (9%)</td><td rowspan="1" colspan="1" valign="top" align="left">4 (2%)</td><td rowspan="1" colspan="1" valign="top" align="left">6 (6%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1000 mg</td><td rowspan="1" colspan="1" valign="top" align="left">373 (38%)</td><td rowspan="1" colspan="1" valign="top" align="left">65 (32%)</td><td rowspan="1" colspan="1" valign="top" align="left">41 (41%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1200 mg</td><td rowspan="1" colspan="1" valign="top" align="left">463 (47%)</td><td rowspan="1" colspan="1" valign="top" align="left">118 (59%)</td><td rowspan="1" colspan="1" valign="top" align="left">44 (44%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1400 mg</td><td rowspan="1" colspan="1" valign="top" align="left">62 (6%)</td><td rowspan="1" colspan="1" valign="top" align="left">14 (7%)</td><td rowspan="1" colspan="1" valign="top" align="left">8 (8%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">PegIFN starting dose (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> PegIFN-α-2b 1.0</td><td rowspan="1" colspan="1" valign="top" align="left">332 (34%)</td><td rowspan="1" colspan="1" valign="top" align="left">71 (35%)</td><td rowspan="1" colspan="1" valign="top" align="left">31 (31%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.8532</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> PegIFN-α-2b 1.5</td><td rowspan="1" colspan="1" valign="top" align="left">321 (33%)</td><td rowspan="1" colspan="1" valign="top" align="left">62 (31%)</td><td rowspan="1" colspan="1" valign="top" align="left">37 (37%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> PegIFN-α-2a</td><td rowspan="1" colspan="1" valign="top" align="left">331 (34%)</td><td rowspan="1" colspan="1" valign="top" align="left">68 (34%)</td><td rowspan="1" colspan="1" valign="top" align="left">31 (31%)</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Baseline Pl count (×10<sup>9</sup>/L)</td><td rowspan="1" colspan="1" valign="top" align="left">225 (184-269)</td><td rowspan="1" colspan="1" valign="top" align="left">228 (184-273)</td><td rowspan="1" colspan="1" valign="top" align="left">230 (186-275)</td><td rowspan="1" colspan="1" valign="top" align="left">0.8977</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Baseline Pl count &lt;100×10<sup>9</sup>/L</td><td rowspan="1" colspan="1" valign="top" align="left">17 (1.7%)</td><td rowspan="1" colspan="1" valign="top" align="left">2 (1%)</td><td rowspan="1" colspan="1" valign="top" align="left">1 (1%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.6724</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Wk 4 Pl reduction (×10<sup>9</sup>/L)</td><td rowspan="1" colspan="1" valign="top" align="left">37 (11-72)</td><td rowspan="1" colspan="1" valign="top" align="left">28 (0-61)</td><td rowspan="1" colspan="1" valign="top" align="left">26 (2-65)</td><td rowspan="1" colspan="1" valign="top" align="left">0.0052</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Wk 4 Pl count (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;75×10<sup>9</sup>/L</td><td rowspan="1" colspan="1" valign="top" align="left">24 (2%)</td><td rowspan="1" colspan="1" valign="top" align="left">4 (2%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.2796</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;50×10<sup>9</sup>/L</td><td rowspan="1" colspan="1" valign="top" align="left">2 (&lt;1%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.7369</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;25×10<sup>9</sup>/L</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">1.0000</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">No (ANC analysis)</td><td rowspan="1" colspan="1" valign="top" align="left">991</td><td rowspan="1" colspan="1" valign="top" align="left">203</td><td rowspan="1" colspan="1" valign="top" align="left">98</td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Baseline ANC count (/mm<sup>3</sup>)</td><td rowspan="1" colspan="1" valign="top" align="left">3.65 (2.96-4.68)</td><td rowspan="1" colspan="1" valign="top" align="left">3.04 (2.14-4.04)</td><td rowspan="1" colspan="1" valign="top" align="left">3.36 (2.77-4.24)</td><td rowspan="1" colspan="1" valign="top" align="left">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Week 4 ANC reduction (/mm<sup>3</sup>)</td><td rowspan="1" colspan="1" valign="top" align="left">2.0 (1.34-2.68)</td><td rowspan="1" colspan="1" valign="top" align="left">1.22 (0.61-1.97)</td><td rowspan="1" colspan="1" valign="top" align="left">1.72 (1.0-2.38)</td><td rowspan="1" colspan="1" valign="top" align="left">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;1.0/mm<sup>3</sup> (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left">124 (13%)</td><td rowspan="1" colspan="1" valign="top" align="left">26 (13%)</td><td rowspan="1" colspan="1" valign="top" align="left">12 (12%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.9892</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;0.75/mm<sup>3</sup> (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left">30 (3%)</td><td rowspan="1" colspan="1" valign="top" align="left">8 (4%)</td><td rowspan="1" colspan="1" valign="top" align="left">1 (1%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.3816</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> &lt;0.5/mm<sup>3</sup> (n, %)</td><td rowspan="1" colspan="1" valign="top" align="left">2 (&lt;1%)</td><td rowspan="1" colspan="1" valign="top" align="left">2 (1%)</td><td rowspan="1" colspan="1" valign="top" align="left">0 (0%)</td><td rowspan="1" colspan="1" valign="top" align="left">0.1588</td></tr></tbody></table></div><div id="largeobj_idm140549831807936" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3634361/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>*</sup>Continuous data are presented as median (25th – 75th centile).</div></div></div><p id="P14">6 SNPs on chromosome 20 were significantly associated with Pl reduction at week 4 (top SNP rs965469, <em>p</em> = 9.02 × 10<sup>−10</sup> in European Americans, <a href="/pmc/articles/PMC3634361/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a> and <a href="/pmc/articles/PMC3634361/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). These SNPs have previously been shown to co-segregate with 2 functional variants in the <em>ITPA</em> gene on chromosome 20, rs1127354 and rs7270101 (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Material III</a>), that are each independently associated with reduced ITPase activity and protect against RBV-induced hemolytic anemia (HA) [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766612">12</a>]. rs1127354 is a mis-sense variant in exon 2 of the <em>ITPA</em> gene (P32T), and rs7270101 is splicing-altering variant located in the second intron (IVS2). Neither variant was included on the genome-wide array but they had been genotyped in the context of a previous GWAS [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766570">12</a>]. These 2 functional variants showed strong independent associations with week 4 Pl reduction (rs1127354, overall <em>p</em> = 10<sup>−12</sup> and rs7270101 <em>p</em> = 10<sup>−7</sup>, respectively, <a href="/pmc/articles/PMC3634361/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The level of ITPase activity may be predicted according to an individual's <em>ITPA</em> genotype, based on previous functional studies (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Material III</a>), and a combined low activity allele made up of either functional variant may be used to define an ITPase deficiency variable [<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766599">21</a>–<a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766585">25</a>]. This ITPase deficiency variable was more strongly associated with Pl reduction (<em>p</em> = 10<sup>−20</sup>). Furthermore, when the two functional <em>ITPA</em> variants were incorporated into a regression model, they were found to entirely explain the genome-wide significant association between rs965469 and Pl reduction (European American patients: <em>p</em> value fell from <em>p</em> = 10<sup>−10</sup> to <em>p</em> = 0.9204 after adjustment for the 2 functional variants, <a href="/pmc/articles/PMC3634361/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The functional <em>ITPA</em> variants remained strongly associated with Pl reduction in this model.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC3634361/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549845286832" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.
Object name is nihms380106f1.jpg" title="An external file that holds a picture, illustration, etc.
Object name is nihms380106f1.jpg" src="/pmc/articles/PMC3634361/bin/nihms380106f1.jpg"></div></a><div id="largeobj_idm140549845286832" class="largeobj-link align_right" style="display: none"><a href="/pmc/articles/PMC3634361/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a target="object" href="/pmc/articles/PMC3634361/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC3634361/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig. 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>The Manhattan plot shows a genome-wide view of the <em>p</em> values [2log<sub>10</sub>(P)] for association between SNPs tested and week 4 platelet reduction in patients of European American ancestry</strong><p id="__p23">The SNPs that show genome-wide significant association with quantitative reduction in Pl levels are marked in red. [This figure appears in color on the web.]</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>(A) Six variants in the 20p13 were associated with Pl reduction at the genome-wide significant level. These tag SNPs have previously been shown to be in linkage disequilibrium with 2 functional variants in the <em>ITPA</em> gene, which cause ITPase deficiency. (B) The two functional <em>ITPA</em> variants rs1127354 and rs7270101 entirely explained the GWAS association signals detected in the region. The adjusted <em>p</em> value (*) was obtained for each SNP in a linear regression model in which the two <em>ITPA</em> functional variants are incorporated</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549846658400" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="5" rowspan="1" valign="top" align="left"><strong>A</strong></th></tr><tr><th colspan="5" rowspan="1" valign="bottom" align="left">
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="top" align="left">Wk 4 Pl reduction</th><th rowspan="1" colspan="1" valign="top" align="left">European Americans</th><th rowspan="1" colspan="1" valign="top" align="left">African Americans</th><th rowspan="1" colspan="1" valign="top" align="left">Hispanics</th><th rowspan="1" colspan="1" valign="top" align="left">Combined <em>p</em> value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1" valign="top" align="left">Top discovery SNPs (Illumina 610 chip)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs965469</td><td rowspan="1" colspan="1" valign="top" align="left">9.02×10<sup>−10</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.1818</td><td rowspan="1" colspan="1" valign="top" align="left">0.0792</td><td rowspan="1" colspan="1" valign="top" align="left">1.29×10<sup>−9</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs3310</td><td rowspan="1" colspan="1" valign="top" align="left">1.30×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.4035</td><td rowspan="1" colspan="1" valign="top" align="left">0.0816</td><td rowspan="1" colspan="1" valign="top" align="left">3.91×10<sup>−9</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051702</td><td rowspan="1" colspan="1" valign="top" align="left">1.30×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.4621</td><td rowspan="1" colspan="1" valign="top" align="left">0.0812</td><td rowspan="1" colspan="1" valign="top" align="left">4.41×10<sup>−9</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051762</td><td rowspan="1" colspan="1" valign="top" align="left">2.76×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.5050</td><td rowspan="1" colspan="1" valign="top" align="left">0.1118</td><td rowspan="1" colspan="1" valign="top" align="left">1.28×10<sup>−8</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051841</td><td rowspan="1" colspan="1" valign="top" align="left">2.16×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.0858</td><td rowspan="1" colspan="1" valign="top" align="left">0.1424</td><td rowspan="1" colspan="1" valign="top" align="left">2.09×10<sup>−8</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051693</td><td rowspan="1" colspan="1" valign="top" align="left">2.21×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.3207</td><td rowspan="1" colspan="1" valign="top" align="left">0.0953</td><td rowspan="1" colspan="1" valign="top" align="left">4.96×10<sup>−8</sup></td></tr><tr><td colspan="5" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"><em>ITPA</em> variants</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1127354 (P32T)</td><td rowspan="1" colspan="1" valign="top" align="left">1.70×10<sup>−10</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.0005</td><td rowspan="1" colspan="1" valign="top" align="left">0.0600</td><td rowspan="1" colspan="1" valign="top" align="left">1.38×10<sup>−12</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7270101 (IVS2)</td><td rowspan="1" colspan="1" valign="top" align="left">9.95×10<sup>−6</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.0038</td><td rowspan="1" colspan="1" valign="top" align="left">0.0231</td><td rowspan="1" colspan="1" valign="top" align="left">3.39×10<sup>−7</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">ITPase deficiency variable</td><td rowspan="1" colspan="1" valign="top" align="left">2.05×10<sup>−16</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.00002</td><td rowspan="1" colspan="1" valign="top" align="left">0.0021</td><td rowspan="1" colspan="1" valign="top" align="left">8.42×10<sup>−20</sup></td></tr></tbody></table></div><div id="largeobj_idm140549846658400" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3634361/table/T2/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549839645792" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="5" rowspan="1" valign="top" align="left"><strong>B</strong></th></tr><tr><th colspan="4" rowspan="1" valign="bottom" align="left">
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="top" align="left">GWAS hit</th><th rowspan="1" colspan="1" valign="top" align="left">Population</th><th rowspan="1" colspan="1" valign="top" align="left">GWAS <em>p</em> value</th><th rowspan="1" colspan="1" valign="top" align="left">Adjusted <em>p</em> value<sup>*</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs965469</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">9.02×10<sup>−10</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.9204</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs3310</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">1.30×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.7914</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051702</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">1.30×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.7914</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051762</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">2.76×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.8065</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051841</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">2.16×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.9204</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6051693</td><td rowspan="1" colspan="1" valign="top" align="left">European Americans</td><td rowspan="1" colspan="1" valign="top" align="left">2.21×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.8876</td></tr></tbody></table></div><div id="largeobj_idm140549839645792" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3634361/table/T2/?report=objectonly">Open in a separate window</a></div></div><p id="P15">Whereas the <em>ITPA</em> variants associated with ITPase deficiency have previously been shown to protect against RBV-induced hemolytic anemia [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766603">12</a>], in this study they were associated with more pronounced reduction of Pl counts. The decline in platelet counts that occurs during antiviral therapy is known to be less pronounced when IFN is combined with RBV than in the setting of IFN monotherapy [<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766575">26</a>,<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766587">27</a>]. This has been attributed to a relative thrombocytosis occurring in response to RBV-induced hemolysis. In the current cohort, a negative correlation was noted between week 4 hemoglobin (Hb) reduction and Pl reduction (European Americans, r = −0.28, <em>p</em> value = 10<sup>−17</sup>, <a href="/pmc/articles/PMC3634361/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a>). Inclusion of week 4 Hb reduction in the same model with the ITPase deficiency variable largely attenuated the strength of the association with Pl reduction (European Americans, from <em>p</em> = 10<sup>−16</sup> to <em>p</em> = 10<sup>−6</sup>, <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table 5</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC3634361/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549845283760" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.
Object name is nihms380106f2.jpg" title="An external file that holds a picture, illustration, etc.
Object name is nihms380106f2.jpg" src="/pmc/articles/PMC3634361/bin/nihms380106f2.jpg"></div></a><div id="largeobj_idm140549845283760" class="largeobj-link align_right" style="display: none"><a href="/pmc/articles/PMC3634361/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a target="object" href="/pmc/articles/PMC3634361/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC3634361/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Fig. 2</a></div><!--caption a7--><div class="caption"><p id="__p24">Correlation of Pl reduction at week 4 (× 10<sup>9</sup>/L) with hemoglobin reduction at week 4 (g/dl), limited to the patients of European American ancestry.</p></div></div></div><p id="P16">In order to evaluate the clinical relevance of this observation we considered the relationship between the ITPase deficiency variable and reductions of Pl count over the course of therapy. The ITPase deficiency variable was significantly associated with more profound reductions in Pl count at week 4, 12, and 24 (<a href="/pmc/articles/PMC3634361/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a>). Beyond week 24, there were non-significant trends in the same direction. Despite this, the number of patients in whom Pl levels fell to below 50 × 10<sup>9</sup>/L, the level at which dose reduction is indicated, was low (&lt;1.5% at any time point) and there were no significant differences in the frequency of Pl &lt;50 × 10<sup>9</sup>/ L according to predicted ITPase deficiency (data not shown). This was true both for the overall cohort, as well as an analysis limited just to those patients treated with pegIFN-alfa-2a 180 μg/week or pegIFN-alfa-2b 1.5 μg/kg/week.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC3634361/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140549836854208" class="figure"><a href="/pmc/articles/PMC3634361/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3634361_nihms380106f3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms380106f3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3634361/bin/nihms380106f3.jpg"></a></div><div id="largeobj_idm140549836854208" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3634361/figure/F3/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC3634361/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Fig. 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Median platelet count over time (× 10<sup>9</sup>/L) according to predicted ITPase deficiency in the overall population</strong><p id="__p25">All patients included in the analysis were &gt;80% adherent to week 4 (n = 1284); for time points beyond week 4, patients were included if they remained on treatment, and a platelet count was available. WT = wildtype (normal ITPase activity); + = mild ITPase deficiency; ++ = moderate ITPase deficiency; +++ = severe ITPase deficiency.</p></div></div></div><p id="P17" class="p p-last">Finally, genetic variation in the region of the <em>IL28B</em> gene on chromosome 19 is strongly associated with the pegIFN and RBV response rate [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766579">8</a>,<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766574">10</a>,<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766571">11</a>,<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766584">28</a>]. No relationship between <em>IL28B</em> genotype and week 4 thrombocytopenia was noted in the 3 ethnic populations.</p></div><div id="S13" class="sec"><h3 id="S13title">Interferon-alfa-mediated neutropenia</h3><p id="P18" class="p p-first">We performed a second genome-wide analysis focused on the genetic determinants of week 4 reductions in ANC as a continuous variable. The final analysis included 1292 patients (European Americans = 991, African Americans = 203, Hispanics = 98). At baseline, median ANC were lower in the African American population (European Americans = 3.65 (2.96–4.68), African Americans = 3.04 (2.14–4.04), Hispanics = 3.36 (2.77–4.24), <em>p</em> = 10<sup>−12</sup>). Median ANC reduction at week 4 was then less prominent in the AA population (European Americans = 2.0 (1.34–2.68), African Americans = 1.22 (0.61–1.97), Hispanics = 1.72 (1.0–2.38), <em>p</em> = 10<sup>−18</sup>). We tested for genetic determinants of week 4 ANC reduction using linear regression models including the covariates age, gender, BMI, hepatic fibrosis stage (F0–2 <em>vs</em>. F3–4), pegIFN dose (binary: alfa-2b 1.0 μg/kg/week vs. 1.5 μg/kg/week or alfa-2a 180 μg/week) and baseline neutrophil level. No common genetic variants were associated with treatment-related reduction in ANC at week 4 at the level of genome-wide significance. In particular, <em>IL28B</em> polymorphism was not associated with IFN-related neutropenia.</p><p id="P19" class="p p-last">A genome-wide analysis of baseline ANC was also negative. In the AA population, we noted associations between baseline ANC and <em>DARC</em> gene polymorphism but these did not meet genome-wide significance criteria (top SNp rs3027041, <em>p</em> = 10<sup>−6</sup>, <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Material VI</a>).</p></div><div id="S14" class="sec sec-last"><h3 id="S14title">Genome-wide analysis for variants associated with other leucopenia</h3><p id="P20" class="p p-first-last">We were also interested in identifying common genetic variants associated with baseline and pegIFN-related week 4 reductions in other white cell counts. Lymphocyte, monocyte, basophil, and eosinophil count were all considered separately. No significant associations were observed in any of these analyses (data not shown).</p></div></div><div id="S15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S15title">Discussion</h2><p id="P21" class="p p-first">To our knowledge this is the first study to consider genetic determinants of treatment-related cytopenia using a genome-wide approach in chronic hepatitis C patients. We have identified an association between <em>ITPA</em> variants causing ITPase deficiency and treatment related thrombocytopenia. We did not detect any common genetic variants that influenced IFN-related neutropenia or leukopenia, an important negative finding. Of note, <em>IL28B</em> polymorphisms, recently identified to be strongly associated with pegIFN plus RBV treatment outcome, were not associated with IFN-related cytopenia.</p><p id="P22">Two functional variants in the <em>ITPA</em> gene that cause ITPase deficiency, red cell ITp accumulation and protection against RBV-induced HA [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766569">12</a>,<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766583">14</a>] were associated with more profound pegIFN-induced thrombocytopenia. This association was largely explained by a relative, reactive thrombocytosis in response to RBV-induced HA in those patients with wildtype ITPase activity. Thus the RBV-induced anemia attenuated the pegIFN effect to reduce Pl counts. Thrombocytosis is well-described as a consequence of hemolytic anemia [<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766616">29</a>], which is in keeping with the original observation in the late 1990s that on-treatment reductions of Pl counts were less marked following the addition of RBV to standard-of-care HCV therapy [<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766595">26</a>,<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766590">27</a>]. This therefore represents an indirect genetic association, where wildtype ITPase activity is associated with more profound RBV-related anemia, which in turn stimulates Pl production, manifesting as less pronounced pegIFN-induced thrombocytopenia. The <em>ITPA</em> variants, which protect against RBV-hemolysis, are therefore associated with greater IFN-induced thrombocytopenia. The biological mechanism underlying this relationship between Hb levels and Pl counts is not clearly understood, but may involve stimulation of the bipotent erythroid/megakaryocyte progenitor cell by erythropoietin [<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766615">30</a>,<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766578">31</a>]. Although adjustment for Hb reduction in the linear regression model largely attenuated the association between the <em>ITPA</em> variants and Pl counts, a residual association with the combined ‘low activity’ allele persisted (European Americans, <em>p</em> = 10<sup>−16</sup> reduced to <em>p</em> = 10<sup>−6</sup>). Although this association was not genome-wide significant, we cannot exclude the possibility of two separate phenomena, with a weaker secondary effect due to a biological relationship between <em>ITPA</em> variants, exogenous IFN and Pl levels. This will require further mechanistic studies.</p><p id="P23">Despite the strong statistical association between <em>ITPA</em> variants, Hb reduction and Pl counts, the clinical relevance of this finding remains uncertain. Relatively few patients decreased their Pl counts to levels requiring dose reduction. It is likely that <em>ITPA</em> genotyping may find a role in predicting RBV-induced anemia in high risk individuals [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766613">12</a>,<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766606">13</a>], but on the basis of the current data, there does not appear to be great clinical utility for predicting severe thrombocytopenia. We note that the current dataset did not include significant numbers of patients with advanced stage fibrosis, and it will be important to assess whether <em>ITPA</em> variants may predict treatment-limiting Pl reductions in this population.</p><p id="P24">No common genetic variants were associated with pegIFN-induced neutropenia or leucopenia. It was interesting that the hematological complications of IFN therapy were not associated with <em>IL28B</em> variants. Although a negative result, this has important implications for our understanding of the biology of the <em>IL28B</em>–pegIFN interaction. The data suggest that the biology of the <em>IL28B</em>–pegIFN treatment response association in HCV is not directly relevant to pegIFN-induced bone marrow suppression. <em>IL28B</em> polymorphism is strongly associated with on-treatment viral kinetics and pegIFN plus RBV treatment outcome [<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_342976791">9</a>]. Although the mechanism by which <em>IL28B</em> variation effects pegIFN sensitivity remains unclear, there is evidence that levels of intrahepatic ISG expression are important [<a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766605">32</a>,<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_342976790">33</a>] and the effect is believed to primarily reflect sensitivity to exogenous IFN. The current data suggest that this is a liver-specific phenomenon. IFN-λ is induced by similar stimuli to type 1 IFN, and shares a common downstream signaling pathway, however the expression of the IFN-λ-receptor (IFNLR) is more restricted than that of the ubiquitous IFN-α-receptor (IFNABR). Although the IFNLR has been shown to be expressed by hepatocytes, IFNLR gene expression is not expressed in hematopoietic cells, with the exception of B lymphocytes [<a href="#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766596">34</a>,<a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766581">35</a>]. Consistent with this, minimal bone marrow suppression was observed in a recent early phase clinical trial using IFN-λ-1 for the treatment of HCV, despite good antiviral potency [<a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308766577">36</a>]. The IL28B polymorphism may therefore act to regulate IFN-α signaling, which is dependent on co-expression of the IFNLR and the IFNABR within the same tissue.</p><p id="P25" class="p p-last">In conclusion, two functional variants in the <em>ITPA</em> gene that are strongly associated with protection from RBV-induced HA are also associated with greater thrombocytopenia in chronic hepatitis C patients. This association is largely explained by a relative reactive thrombocytosis in response to RBV-induced HA, which attenuates IFN-related thrombocytopenia.</p></div><div id="S17" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S17title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Suppl data</h4><div class="sup-box half_rhythm" id="d36e972"><a href="/pmc/articles/PMC3634361/bin/NIHMS380106-supplement-Suppl_data.doc" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(3.9M, doc)</sup></div></div></div><div id="S16" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S16title">Acknowledgments</h2><div class="sec"><p id="__p2">We are indebted to the IDEAL principal investigators, the study coordinators, nurses and patients involved in the study.</p><p id="__p3"><strong>Financial support</strong>: This study was funded by Schering-Plough Research Institute, Kenilworth, New Jersey. Dr. Thompson received funding support from the Duke Clinical Research Institute, a generous research gift from the Richard B. Boebel Family Fund, the National Health and Medical Research Council of Australia, the Gastroenterology Society of Australia and the Royal Australasian College of Physicians.</p></div></div><div id="GL" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="GLtitle">Abbreviations</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td id="G1">HCV</td><td>hepatitis C virus</td></tr><tr><td id="G2">pegIFN</td><td>pegylated-interferon-alfa</td></tr><tr><td id="G3">RBV</td><td>ribavirin</td></tr><tr><td id="G4">DARC</td><td>Duffy Antigen Receptor for Chemokines</td></tr><tr><td id="G5">IL28B</td><td>Iinterleukin 28B</td></tr><tr><td id="G6">ITPA</td><td>inosine triphosphatase gene</td></tr><tr><td id="G7">ITPase</td><td>inosine triphosphatase</td></tr><tr><td id="G8">ANC</td><td>absolute neutrophil count</td></tr><tr><td id="G9">Pl</td><td>platelet</td></tr><tr><td id="G10">Hb</td><td>hemoglobin</td></tr><tr><td id="G11">SNP</td><td>single nucleotide polymorphism</td></tr><tr><td id="G12">GWAS</td><td>genome-wide association study</td></tr><tr><td id="G13">BMI</td><td>body mass index</td></tr><tr><td id="G14">HA</td><td>he-molytic anemia</td></tr><tr><td id="G15">IFNLR</td><td>IFN-λ-receptor</td></tr><tr><td id="G16">IFNABR</td><td>IFN-α-receptor</td></tr></tbody></table></div></div></div><div id="idm140549840578240" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140549840578240title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN3"> </p><p id="__p4" class="p p-first-last"><strong>Conflict of interest</strong>: Drs. McHutchison, Goldstein, Muir, Afdhal, Jacobson, Esteban, Poordad, Lawitz, McCone, Shiffman, King, Kwo, Patel and Sulkowski report having received research and grant support from Schering-Plough. Drs. McHutchison, Goldstein, Muir, Afdhal, Jacobson, Esteban, Poordad, Lawitz, Shiffman, Kwo, and Sulkowski have reported receiving consulting fees or acted in an advisory capacity for Schering-Plough. Drs. Noviello, Pedicone, Brass, Pedicone, and Albrecht are employees of Schering-Plough (now Merck &amp; Co., Inc.) and are stock holders in this entity. Drs. Thompson, Goldstein, McHutchison, Ge, Fellay, Shianna, and Urban are co-inventors of a patent application based on the ITPA finding.</p><p></p><div><p id="__p5" class="p p-first-last"><strong>Author contributions</strong>: A.J.T. performed the primary data analysis and wrote the first draft of the manuscript with assistance and revision from P.J.C., D.G., A.S., J.F., M.F., Q.Z., A.J.M., and J.G.M. D.G., J.F., K.V.S., T.U., and D.B.G. were responsible for genotyping the ITPA variants. J.G.M. and M.S.S. were the principal investigators for the IDEAL study, and together with D.B.G., S.N., L.D.P., C.A.B., and J.K.A., developed the pharmacogenomic study protocol. A.J.M., N.H.A., I.M.J., F.P., E.J.L., J.M., M.L.S., G.W.G., J.W.K., P.Y.K., and K.P. were site investigators for the IDEAL study. All authors had full access to the data in the study and contributed to the interpretation of the results. All authors reviewed the manuscript and provided further contributions and suggestions. All authors read and approved the final manuscript.</p></div><p class="fn sec" id="FN5"></p><p id="__p6" class="p p-first-last"><strong>Supplementary data</strong>: <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary data</a> associated with this article can be found, in the online version, at doi:10.1016/j.jhep.2011.04.021.</p><p></p></div></div><div id="idm140549844338896" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140549844338896title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Lavanchy D. The global burden of hepatitis C. <span><span class="ref-journal">Liver Int. </span>2009;<span class="ref-vol">29</span>:74–81.</span> [<a href="/pubmed/19207969" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Liver+Int&amp;title=The+global+burden+of+hepatitis+C&amp;author=D+Lavanchy&amp;volume=29&amp;publication_year=2009&amp;pages=74-81&amp;pmid=19207969&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">347</span>:975–982.</span> [<a href="/pubmed/12324553" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Peginterferon+alfa-2a+plus+ribavirin+for+chronic+hepatitis+C+virus+infection&amp;author=MW+Fried&amp;author=ML+Shiffman&amp;author=KR+Reddy&amp;author=C+Smith&amp;author=G+Marinos&amp;volume=347&amp;publication_year=2002&amp;pages=975-982&amp;pmid=12324553&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. <span><span class="ref-journal">Lancet. </span>2001;<span class="ref-vol">358</span>:958–965.</span> [<a href="/pubmed/11583749" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Peginterferon+alfa-2b+plus+ribavirin+compared+with+interferon+alfa-2b+plus+ribavirin+for+initial+treatment+of+chronic+hepatitis+C:+a+randomised+trial&amp;author=MP+Manns&amp;author=JG+McHutchison&amp;author=SC+Gordon&amp;author=VK+Rustgi&amp;author=M+Shiffman&amp;volume=358&amp;publication_year=2001&amp;pages=958-965&amp;pmid=11583749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. <span><span class="ref-journal">Gastroenterology. </span>2002;<span class="ref-vol">123</span>:1061–1069.</span> [<a href="/pubmed/12360468" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Adherence+to+combination+therapy+enhances+sustained+response+in+genotype-1-infected+patients+with+chronic+hepatitis+C&amp;author=JG+McHutchison&amp;author=M+Manns&amp;author=K+Patel&amp;author=T+Poynard&amp;author=KL+Lindsay&amp;volume=123&amp;publication_year=2002&amp;pages=1061-1069&amp;pmid=12360468&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Tillmann HL, Patel K, McHutchison JG. Role of growth factors and throm-bopoietic agents in the treatment of chronic hepatitis C. <span><span class="ref-journal">Curr Gastroenterol Rep. </span>2009;<span class="ref-vol">11</span>:5–14.</span> [<a href="/pubmed/19166653" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Gastroenterol+Rep&amp;title=Role+of+growth+factors+and+throm-bopoietic+agents+in+the+treatment+of+chronic+hepatitis+C&amp;author=HL+Tillmann&amp;author=K+Patel&amp;author=JG+McHutchison&amp;volume=11&amp;publication_year=2009&amp;pages=5-14&amp;pmid=19166653&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? <span><span class="ref-journal">J Lab Clin Med. </span>1999;<span class="ref-vol">133</span>:15–22.</span> [<a href="/pubmed/10385477" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Lab+Clin+Med&amp;title=Benign+ethnic+neutropenia:+what+is+a+normal+absolute+neutrophil+count?&amp;author=TB+Haddy&amp;author=SR+Rana&amp;author=O+Castro&amp;volume=133&amp;publication_year=1999&amp;pages=15-22&amp;pmid=10385477&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al.  Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. <span><span class="ref-journal">PLoS Genet. </span>2009;<span class="ref-vol">5</span>:e1000360.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2628742/">PMC free article</a>]</span> [<a href="/pubmed/19180233" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genet&amp;title=Reduced+neutrophil+count+in+people+of+African+descent+is+due+to+a+regulatory+variant+in+the+Duffy+antigen+receptor+for+chemokines+gene&amp;author=D+Reich&amp;author=MA+Nalls&amp;author=WH+Kao&amp;author=EL+Akylbekova&amp;author=A+Tandon&amp;volume=5&amp;publication_year=2009&amp;pages=e1000360&amp;pmid=19180233&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. <span><span class="ref-journal">Nature. </span>2009;<span class="ref-vol">461</span>:399–401.</span> [<a href="/pubmed/19684573" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Genetic+variation+in+IL28B+predicts+hepatitis+C+treatment-induced+viral+clearance&amp;author=D+Ge&amp;author=J+Fellay&amp;author=AJ+Thompson&amp;author=JS+Simon&amp;author=KV+Shianna&amp;volume=461&amp;publication_year=2009&amp;pages=399-401&amp;pmid=19684573&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Thompson AJ, Muir A, Sulkowski M, et al.   <span class="ref-journal">IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients gastroenterology.</span> 2010.  Epub ahead of print. [<a href="/pubmed/20399780" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=IL28B+polymorphism+improves+viral+kinetics+and+is+the+strongest+pre-treatment+predictor+of+SVR+in+HCV-1+patients+gastroenterology&amp;author=AJ+Thompson&amp;author=A+Muir&amp;author=M+Sulkowski&amp;publication_year=2010&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:1100–1104.</span> [<a href="/pubmed/19749758" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=IL28B+is+associated+with+response+to+chronic+hepatitis+C+interferon-alpha+and+ribavirin+therapy&amp;author=V+Suppiah&amp;author=M+Moldovan&amp;author=G+Ahlenstiel&amp;author=T+Berg&amp;author=M+Weltman&amp;volume=41&amp;publication_year=2009&amp;pages=1100-1104&amp;pmid=19749758&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:1105–1109.</span> [<a href="/pubmed/19749757" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Genome-wide+association+of+IL28B+with+response+to+pegylated+interferon-alpha+and+ribavirin+therapy+for+chronic+hepatitis+C&amp;author=Y+Tanaka&amp;author=N+Nishida&amp;author=M+Sugiyama&amp;author=M+Kurosaki&amp;author=K+Matsuura&amp;volume=41&amp;publication_year=2009&amp;pages=1105-1109&amp;pmid=19749757&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <span><span class="ref-journal">Nature. </span>2010;<span class="ref-vol">464</span>:405–408.</span> [<a href="/pubmed/20173735" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=ITPA+gene+variants+protect+against+anaemia+in+patients+treated+for+chronic+hepatitis+C&amp;author=J+Fellay&amp;author=AJ+Thompson&amp;author=D+Ge&amp;author=CE+Gumbs&amp;author=TJ+Urban&amp;volume=464&amp;publication_year=2010&amp;pages=405-408&amp;pmid=20173735&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. <span><span class="ref-journal">Gastroenterology. </span>2010;<span class="ref-vol">139</span>:1181–1189.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3086671/">PMC free article</a>]</span> [<a href="/pubmed/20547162" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Variants+in+the+ITPA+gene+protect+against+ribavirin-induced+hemolytic+anemia+and+decrease+the+need+for+ribavirin+dose+reduction&amp;author=AJ+Thompson&amp;author=J+Fellay&amp;author=K+Patel&amp;author=HL+Tillmann&amp;author=S+Naggie&amp;volume=139&amp;publication_year=2010&amp;pages=1181-1189&amp;pmid=20547162&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al.  Inosine triphosphate protects against ribavirin-induced adenosine triphos-phate loss by restoring adenylosuccinate synthase function. <span><span class="ref-journal">Gastroenterology. </span>2011;<span class="ref-vol">140</span>:1314–1321.</span> [<a href="/pubmed/21199653" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Inosine+triphosphate+protects+against+ribavirin-induced+adenosine+triphos-phate+loss+by+restoring+adenylosuccinate+synthase+function&amp;author=Y+Hitomi&amp;author=ET+Cirulli&amp;author=J+Fellay&amp;author=JG+McHutchison&amp;author=AJ+Thompson&amp;volume=140&amp;publication_year=2011&amp;pages=1314-1321&amp;pmid=21199653&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al.  Peginterferon Alfa-2b or Alfa-2a with ribavirin for treatment of hepatitis C infection. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>:580–593.</span> [<a href="/pubmed/19625712" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Peginterferon+Alfa-2b+or+Alfa-2a+with+ribavirin+for+treatment+of+hepatitis+C+infection&amp;author=JG+McHutchison&amp;author=EJ+Lawitz&amp;author=ML+Shiffman&amp;author=AJ+Muir&amp;author=GW+Galler&amp;volume=361&amp;publication_year=2009&amp;pages=580-593&amp;pmid=19625712&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:2265–2271.</span> [<a href="/pubmed/15163776" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Peginterferon+alfa-2b+and+ribavirin+for+the+treatment+of+chronic+hepatitis+C+in+blacks+and+non-Hispanic+whites&amp;author=AJ+Muir&amp;author=JD+Bornstein&amp;author=PG+Killenberg&amp;volume=350&amp;publication_year=2004&amp;pages=2265-2271&amp;pmid=15163776&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. <span><span class="ref-journal">Nature. </span>2009;<span class="ref-vol">461</span>:798–801.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3172006/">PMC free article</a>]</span> [<a href="/pubmed/19759533" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Genetic+variation+in+IL28B+and+spontaneous+clearance+of+hepatitis+C+virus&amp;author=DL+Thomas&amp;author=CL+Thio&amp;author=MP+Martin&amp;author=Y+Qi&amp;author=D+Ge&amp;volume=461&amp;publication_year=2009&amp;pages=798-801&amp;pmid=19759533&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:559–575.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+a+tool+set+for+whole-genome+association+and+population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;author=L+Thomas&amp;author=MA+Ferreira&amp;volume=81&amp;publication_year=2007&amp;pages=559-575&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. <span><span class="ref-journal">J Evol Biol. </span>2005;<span class="ref-vol">18</span>:1368–1373.</span> [<a href="/pubmed/16135132" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Evol+Biol&amp;title=Combining+probability+from+independent+tests:+the+weighted+Z-method+is+superior+to+Fisher's+approach&amp;author=MC+Whitlock&amp;volume=18&amp;publication_year=2005&amp;pages=1368-1373&amp;pmid=16135132&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:904–909.</span> [<a href="/pubmed/16862161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Principal+components+analysis+corrects+for+stratification+in+genome-wide+association+studies&amp;author=AL+Price&amp;author=NJ+Patterson&amp;author=RM+Plenge&amp;author=ME+Weinblatt&amp;author=NA+Shadick&amp;volume=38&amp;publication_year=2006&amp;pages=904-909&amp;pmid=16862161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <span><span class="ref-journal">Nature. </span>2010;<span class="ref-vol">464</span>:405–408.</span> [<a href="/pubmed/20173735" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=ITPA+gene+variants+protect+against+anaemia+in+patients+treated+for+chronic+hepatitis+C&amp;author=J+Fellay&amp;author=AJ+Thompson&amp;author=D+Ge&amp;author=CE+Gumbs&amp;author=TJ+Urban&amp;volume=464&amp;publication_year=2010&amp;pages=405-408&amp;pmid=20173735&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. <span><span class="ref-journal">Hum Genet. </span>2002;<span class="ref-vol">111</span>:360–367.</span> [<a href="/pubmed/12384777" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Genet&amp;title=Genetic+basis+of+inosine+triphosphate+pyrophosphohydrolase+deficiency&amp;author=S+Sumi&amp;author=AM+Marinaki&amp;author=M+Arenas&amp;author=L+Fairbanks&amp;author=M+Shobowale-Bakre&amp;volume=111&amp;publication_year=2002&amp;pages=360-367&amp;pmid=12384777&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. <span><span class="ref-journal">Clin Chem. </span>2006;<span class="ref-vol">52</span>:240–247.</span> [<a href="/pubmed/16384889" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Chem&amp;title=Measurement+of+erythrocyte+inosine+triphosphate+pyrophosphohydrolase+(ITPA)+activity+by+HPLC+and+correlation+of+ITPA+genotype-phenotype+in+a+Caucasian+population&amp;author=M+Shipkova&amp;author=K+Lorenz&amp;author=M+Oellerich&amp;author=E+Wieland&amp;author=N+von+Ahsen&amp;volume=52&amp;publication_year=2006&amp;pages=240-247&amp;pmid=16384889&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Maeda T, Sumi S, Ueta A, Ohkubo Y, Ito T, Marinaki AM, et al.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. <span><span class="ref-journal">Mol Genet Metab. </span>2005;<span class="ref-vol">85</span>:271–279.</span> [<a href="/pubmed/15946879" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Genet+Metab&amp;title=Genetic+basis+of+inosine+triphosphate+pyrophosphohydrolase+deficiency+in+the+Japanese+population&amp;author=T+Maeda&amp;author=S+Sumi&amp;author=A+Ueta&amp;author=Y+Ohkubo&amp;author=T+Ito&amp;volume=85&amp;publication_year=2005&amp;pages=271-279&amp;pmid=15946879&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Atanasova S, Shipkova M, Svinarov D, Mladenova A, Genova M, Wieland E, et al.  Analysis of ITPA phenotype–genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. <span><span class="ref-journal">Ther Drug Monit. </span>2007;<span class="ref-vol">29</span>:6–10.</span> [<a href="/pubmed/17304144" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Drug+Monit&amp;title=Analysis+of+ITPA+phenotype–genotype+correlation+in+the+Bulgarian+population+revealed+a+novel+gene+variant+in+exon+6&amp;author=S+Atanasova&amp;author=M+Shipkova&amp;author=D+Svinarov&amp;author=A+Mladenova&amp;author=M+Genova&amp;volume=29&amp;publication_year=2007&amp;pages=6-10&amp;pmid=17304144&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) <span><span class="ref-journal">Lancet. </span>1998;<span class="ref-vol">352</span>:1426–1432.</span> [<a href="/pubmed/9807989" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Randomised+trial+of+interferon+alpha2b+plus+ribavirin+for+48+weeks+or+for+24+weeks+versus+interferon+alpha2b+plus+placebo+for+48+weeks+for+treatment+of+chronic+infection+with+hepatitis+C+virus.+International+Hepatitis+Interventional+Therapy+Group+(IHIT)&amp;author=T+Poynard&amp;author=P+Marcellin&amp;author=SS+Lee&amp;author=C+Niederau&amp;author=GS+Minuk&amp;volume=352&amp;publication_year=1998&amp;pages=1426-1432&amp;pmid=9807989&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">339</span>:1493–1499.</span> [<a href="/pubmed/9819447" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Interferon+alfa-2b+alone+or+in+combination+with+ribavirin+for+the+treatment+of+relapse+of+chronic+hepatitis+C.+International+Hepatitis+Interventional+Therapy+Group&amp;author=GL+Davis&amp;author=R+Esteban-Mur&amp;author=V+Rustgi&amp;author=J+Hoefs&amp;author=SC+Gordon&amp;volume=339&amp;publication_year=1998&amp;pages=1493-1499&amp;pmid=9819447&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. <span><span class="ref-journal">Gastroenterology. </span>2010;<span class="ref-vol">139</span>:120–129. e118.</span> [<a href="/pubmed/20399780" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Interleukin-28B+polymorphism+improves+viral+kinetics+and+is+the+strongest+pretreatment+predictor+of+sustained+virologic+response+in+genotype+1+hepatitis+C+virus&amp;author=AJ+Thompson&amp;author=AJ+Muir&amp;author=MS+Sulkowski&amp;author=D+Ge&amp;author=J+Fellay&amp;volume=139&amp;publication_year=2010&amp;pages=120-129&amp;pmid=20399780&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Schafer AI. Thrombocytosis. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:1211–1219.</span> [<a href="/pubmed/15028825" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Thrombocytosis&amp;author=AI+Schafer&amp;volume=350&amp;publication_year=2004&amp;pages=1211-1219&amp;pmid=15028825&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Cardier JE, Erickson-Miller CL, Murphy MJ., Jr Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. <span><span class="ref-journal">Stem Cells. </span>1997;<span class="ref-vol">15</span>:286–290.</span> [<a href="/pubmed/9253112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Stem+Cells&amp;title=Differential+effect+of+erythropoietin+and+GM-CSF+on+megakaryocytopoiesis+from+primitive+bone+marrow+cells+in+serum-free+conditions&amp;author=JE+Cardier&amp;author=CL+Erickson-Miller&amp;author=MJ+Murphy&amp;volume=15&amp;publication_year=1997&amp;pages=286-290&amp;pmid=9253112&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. <span><span class="ref-journal">Blood. </span>1995;<span class="ref-vol">85</span>:1719–1726.</span> [<a href="/pubmed/7535585" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Thrombopoietin+(c-mpl+ligand)+acts+synergistically+with+erythropoietin,+stem+cell+factor,+and+interleukin-11+to+enhance+murine+megakaryocyte+colony+growth+and+increases+megakaryocyte+ploidy+in+vitro&amp;author=VC+Broudy&amp;author=NL+Lin&amp;author=K+Kaushansky&amp;volume=85&amp;publication_year=1995&amp;pages=1719-1726&amp;pmid=7535585&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al.  Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. <span><span class="ref-journal">Gastroenterology. </span>2010;<span class="ref-vol">139</span>:499–509.</span> [<a href="/pubmed/20434452" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Hepatic+ISG+expression+is+associated+with+genetic+variation+in+IL28B+and+the+outcome+of+IFN+therapy+for+chronic+hepatitis+C&amp;author=M+Honda&amp;author=A+Sakai&amp;author=T+Yamashita&amp;author=Y+Nakamoto&amp;author=E+Mizukoshi&amp;volume=139&amp;publication_year=2010&amp;pages=499-509&amp;pmid=20434452&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al.  IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:1888–1896.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3653303/">PMC free article</a>]</span> [<a href="/pubmed/20931559" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=IL28B+genotype+is+associated+with+differential+expression+of+intrahepatic+interferon-stimulated+genes+in+patients+with+chronic+hepatitis+C&amp;author=TJ+Urban&amp;author=AJ+Thompson&amp;author=SS+Bradrick&amp;author=J+Fellay&amp;author=D+Schuppan&amp;volume=52&amp;publication_year=2010&amp;pages=1888-1896&amp;pmid=20931559&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al.  Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. <span><span class="ref-journal">Hepatology. </span>2006;<span class="ref-vol">44</span>:896–906.</span> [<a href="/pubmed/17006906" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Interleukin-29+uses+a+type+1+interferon-like+program+to+promote+antiviral+responses+in+human+hepatocytes&amp;author=SE+Doyle&amp;author=H+Schreckhise&amp;author=K+Khuu-Duong&amp;author=K+Henderson&amp;author=R+Rosler&amp;volume=44&amp;publication_year=2006&amp;pages=896-906&amp;pmid=17006906&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. <span><span class="ref-journal">PLoS Pathog. </span>2008;<span class="ref-vol">4</span>:e1000017.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2265414/">PMC free article</a>]</span> [<a href="/pubmed/18369468" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Pathog&amp;title=IFN-lambda+(IFN-lambda)+is+expressed+in+a+tissue-dependent+fashion+and+primarily+acts+on+epithelial+cells+in+vivo&amp;author=C+Sommereyns&amp;author=S+Paul&amp;author=P+Staeheli&amp;author=T+Michiels&amp;volume=4&amp;publication_year=2008&amp;pages=e1000017&amp;pmid=18369468&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>(3):822–832.</span> [<a href="/pubmed/20564352" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Phase+1b+study+of+pegylated+interferon+lambda+1+with+or+without+ribavirin+in+patients+with+chronic+genotype+1+hepatitis+C+virus+infection&amp;author=AJ+Muir&amp;author=ML+Shiffman&amp;author=A+Zaman&amp;author=B+Yoffe&amp;author=A+de+la+Torre&amp;volume=52&amp;issue=3&amp;publication_year=2010&amp;pages=822-832&amp;pmid=20564352&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3634361&amp;issue-id=222181&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140549843309248title">Abstract</a></li><li><a href="#S5title">Introduction</a></li><li><a href="#S6title">Materials and methods</a></li><li><a href="#S11title">Results</a></li><li><a href="#S15title">Discussion</a></li><li><a href="#S17title">Supplementary Material</a></li><li><a href="#S16title">Acknowledgments</a></li><li><a href="#GLtitle">Abbreviations</a></li><li><a href="#idm140549840578240title">Footnotes</a></li><li><a href="#idm140549844338896title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC3634361/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC3634361/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC3634361/pdf/nihms380106.pdf">PDF (506K)</a></li> | <li><a href="#" data-citationid="PMC3634361" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3634361%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3634361%2F&amp;text=Genome-wide%20association%20study%20of%20interferon-related%20cytopenia%20in%20chronic%20hepatitis%20C%20patients" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3634361%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="21703177" data-aiid="3634361" data-aid="3634361" data-iid="222181" data-domainid="319" data-domain="nihpa" data-accid="PMC3634361" data-md5="1dd52e0761fecd1328dbaaf3523399b2"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T07:19:11-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal104&amp;ncbi_phid=CE8B8D9CDD5231B10000000007EB0500&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3634361%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC3634361/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>